ORUKA THERAPEUTICS INC

Oruka Therapeutics insider buying by CMO Joana Gonçalves signals confidence in its cardiovascular pipeline and commercial strategy, offering investors insight into future upside.

Oruka Therapeutics insider buys by CFO Arjun Agarwal signal confidence in its heart‑failure pipeline, offering investors a bullish cue amid market volatility.

Oruka Therapeutics insider trades reveal routine portfolio rebalancing, not looming corporate events—insight on future stock moves and drug‑development strategy.

Quin Paul T’s $7.80 buy of Oruka Therapeutics shares amid a $1.3 billion convertible note shows disciplined insider buying and confidence in future upside.

Insight into Oruka Therapeutics’ insider trades reveals CMO confidence in its Phase III cardiovascular pipeline, hinting at future upside and potential dilution protection.

Insider buying and selling by Oruka Therapeutics’ leadership shows confidence in its gene‑targeted heart‑failure platform, signaling a promising upside for investors.